Lundin Law PC announces it is investigating claims against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (Nasdaq: TTPH) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Tetraphase were false and misleading and/or failed to disclose material information regarding the Company's financial performance.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at

The investigation will focus on whether Tetraphase issued materially false and misleading statements to investors regarding the efficacy and safety of Eravacycline.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010